Your cart is currently empty!
Sumitomo Pharma Expands Collaboration with Shanghai Pharmaceuticals for Prescription Drug Co-Marketing
•
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) has announced an expanded Contract Sales Organization (CSO) collaboration agreement with Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607; SPH). This new agreement follows the success of their initial collaboration in 2020 and aims to further enhance the co-marketing efforts for prescription drugs. Building…
Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use
•
US-based Boston Scientific Corporation (NYSE: BSX) has announced that China’s National Medical Products Administration (NMPA) has granted approval for its next-generation intravascular ultrasound (IVUS) diagnostic system, AVVIGO+, for use in diagnosing coronary heart disease. This marks a significant advancement in the diagnostic capabilities for cardiovascular healthcare in China. Multimodal Platform…
Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic
•
US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with German pharmaceutical giant Boehringer Ingelheim (BI) to jointly develop and commercialize Guardant360 CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib. This collaboration aims to enhance the treatment landscape for non-small cell lung cancer…
Roche’s Prasinezumab Shows Promise in Phase IIb PADOVA Study for Early-Stage Parkinson’s Disease
•
Swiss pharmaceutical giant Roche (SWX: ROG) has published results from the Phase IIb PADOVA study for its investigational monoclonal antibody, prasinezumab, in patients with early-stage Parkinson’s disease (PD). The study aimed to assess the drug’s impact on the primary endpoint of time to confirmed motor progression, with a hazard ratio…
Hainan Boao Lecheng and Sanofi Partner with Paris-Saclay Cancer Cluster for Advanced Cancer Treatments
•
The Hainan Boao Lecheng International Medical Tourism Pilot Zone, in collaboration with France’s major Sanofi’s (NASDAQ: SNY) China unit and the Paris-Saclay Cancer Cluster (PSCC), has established a tripartite collaboration aimed at advancing healthcare solutions. This partnership is designed to combine the strengths of each organization to enhance the treatment…
Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its sacituzumab tirumotecan (SKB264/MK-2870) in China, marking a significant milestone in the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have been previously treated with at least two…
WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio
•
China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic licensing agreement with compatriot firm Hangzhou DAC Biotechnology Co., Ltd, an antibody drug conjugate (ADC) specialist, and US-based Aadi Bioscience, Inc. (NASDAQ: AADI). The deal grants Aadi Bio global d2018evelopment and commercialization rights to a…
MGI Tech Co., Ltd Partners with Sabin Group to Enhance Genetic Sequencing in Brazil
•
China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has entered into a strategic partnership with Sabin Group, one of the largest diagnostic laboratories in Brazil. This collaboration aims to enhance the accessibility and quality of genetic sequencing services, thereby improving the healthcare standards for the Brazilian population. Financial…
Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB
•
Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo Therapeutics, Inc. (NASDAQ: SGMO). This collaboration will enable Astellas to utilize Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, targeting an undisclosed neurological condition. Financial Terms and Potential Impact on Astellas’ PipelineThe agreement allows…
BioArctic AB Secures Global Rights to PyroGlu-Aβ Antibody Program in BMS Deal
•
Sweden-based BioArctic AB (OTCMKTS: BRCTF) has announced a significant licensing agreement with US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY). The deal grants BMS global exclusive development and commercialization rights to BioArctic’s PyroGlutamate-amyloid (PyroGlu-Aβ) antibody program, which includes BAN1503 and BAN2803. Under the agreement, BioArctic retains the option to co-commercialize…
Fangzhou Inc. Partners with BMS to Innovate Digital Medicine Platform
•
China-based Internet healthcare solutions provider Fangzhou Inc. (HKG: 6086) has entered into a partnership with the China unit of US major Bristol-Myers Squibb (BMS, NYSE: BMY). The collaboration, with financial details undisclosed, aims to jointly develop a digital medicine platform and upgrade the Internet health management model, marking a significant…
Sanofi and Corxel Pharmaceuticals Partner for Aficamten in Greater China Rights
•
Global healthcare leader Sanofi (NASDAQ: SNY) and China-based Corxel Pharmaceuticals (CORXEL), formerly known as Ji Xing Pharmaceuticals, have jointly announced an official agreement. Under this partnership, Sanofi is set to acquire exclusive development and commercialization rights to CORXEL’s aficamten in Greater China. The financial details of the deal have not…
HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies
•
China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has announced receiving a tender offer from its compatriot firm Sino Biopharmaceutical Ltd.’s (HKG: 1177) controlling firm. This strategic move will see a capital infusion of RMB 525 million (USD 72 million), equating to a 55%…
Joincare Pharmaceutical’s JKN2403 Gains NMPA Approval for COPD Clinical Trials
•
China-based Jo2006incare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) is set to advance its Category 1 chemical drug, JKN2403, into clinical trials for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD), following approval from the National Medical Products Administration (NMPA). JKN2403: A Novel COPD Treatment with Promising…
Sino Biopharmaceutical Ltd. Files for Benmelstobart and Anlotinib Combination Therapy in ASPS Treatment
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) is poised to make another indication approval filing with the National Medical Products Administration (NMPA) for its anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) benmelstobart (TQB2450) in combination with the multi-target kinase inhibitor anlotinib. The targeted indication for this combination therapy is advanced alveolar…
HighTide Therapeutics and SSY Group Ltd Join Forces to Tackle Metabolic and Aging Diseases
•
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced a strategic collaboration framework agreement with compatriot firm SSY Group Ltd. (HKG: 2005). The collaboration aims to integrate HighTide’s unique strengths in the multi-system collaborative innovation of natural products with SSY’s extensive experience in activity screening, formulation development, achievement transformation, quality control,…
AIM Vaccine Co., Ltd Receives NMPA Clearance for Innovative Cell-Based Influenza Vaccine
•
AIM Vaccine Co., Ltd (HKG: 6660), a China-based biopharmaceutical company, has announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a clinical study for its suspension cultured quadrivalent MDCK cell influenza vaccine. This marks a significant step forward in the development of a novel…
Henlius Biotech Expands Partnership with Palleon Pharmaceuticals for Autoimmune Disease Treatment
•
Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biotechnology company based in China, has announced an expansion of its alliance with Palleon Pharmaceuticals Inc. This partnership, originally established in June 2022, now includes the US firm in the development and commercialization of a combination therapy using Palleon’s E-602 and Henlius’…
AIM Vaccine Co., Ltd Receives NMPA Approval for Second-Gen Tetanus Vaccine Clinical Trial
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its second-generation high-valent adsorbed tetanus vaccine. This development is a significant step forward in the company’s efforts to combat a disease that is both serious and…
MSD’s Clesrovimab for Infant RSV Protection: FDA Accepts BLA for Review
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for clesrovimab (MK-1654), the company’s investigational prophylactic long-acting monoclonal antibody. This antibody is designed to protect infants from respiratory syncytial virus (RSV) disease during their first…
